Skip to main content

Supreme Court blocks bankruptcy deal for OxyContin maker Purdue Pharma

The U.S. Supreme Court struck down Purdue Pharma's nationwide settlement agreement on Thursday, delaying compensation for opioid victims.

The U.S. Supreme Court voted to block a controversial bankruptcy deal for Purdue Pharma, the drug company at the center of the opioid crisis, on Thursday.

The narrow 5-4 ruling rejected a nationwide bankruptcy settlement from proceeding with the company, and it potentially exposes the company's owners--the Sackler family--to civil consequences.

Purdue Pharma is the creator of OxyCotin and is responsible for proliferating the drug across the U.S.

While the ruling opens the Sackler family up to further consequences, the end of the settlement agreement also further delays compensation for victims of the opioid epidemic.

IRS PENALTIES ON AMERICAN TAXPAYERS SURGED NEARLY 300% LAST YEAR

"From the court overseeing Purdue’s bankruptcy, they sought and won an order extinguishing vast numbers of existing and potential claims against them. They obtained all this without securing the consent of those affected or placing anything approaching their total assets on the table for their creditors. The question we face is whether the bankruptcy code authorizes a court to issue an order like that," the court wrote.

READ THE SUPREME COURT OPINION – APP USERS, CLICK HERE:

This is a developing story. Check back soon for updates.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.